Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9HCE1

UPID:
MOV10_HUMAN

ALTERNATIVE NAMES:
Armitage homolog; Moloney leukemia virus 10 protein

ALTERNATIVE UPACC:
Q9HCE1; Q5JR03; Q8TEF0; Q9BSY3; Q9BUJ9

BACKGROUND:
The Helicase MOV-10 protein, known alternatively as Armitage homolog and Moloney leukemia virus 10 protein, is integral to various cellular functions such as mRNA metabolism, viral infectivity modulation, and synaptic transmission regulation. It enhances type I interferon production for antiviral immunity and inhibits HIV-1 and hepatitis B virus replication. MOV-10 also plays a role in microRNA-mediated gene silencing and is vital for brain development and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Helicase MOV-10 opens avenues for innovative therapeutic approaches. Its critical role in antiviral defense mechanisms positions it as a promising target for developing antiviral therapies. The protein's significance in brain development and function further underscores its potential in treating neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.